Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and immunogenicity of the EV71 vaccine in pediatric subjects aged 6 to 35 months and 3 to 6 years has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enterovirus Infections

Drugs mentioned

• EV71 vaccine (enterovirus 71 vaccine)

Snippet

Sponsor: Enimmune Corporation | Conditions: Enterovirus Infections | Phase 2 | Status: COMPLETED